{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:46:22Z","timestamp":1785901582807,"version":"3.56.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.medj.2026.101187","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:32:49Z","timestamp":1783693969000},"page":"101187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic lupus erythematosus: Phase 2 trials to watch in 2026"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F.","family":"Morand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101187_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101138","article-title":"Systemic lupus erythematosus: Phase 3 clinical trials to watch","volume":"7","author":"Suresh","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.medj.2026.101187_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14712598.2025.2536888","article-title":"Progress in the use of type I interferon blockade in systemic lupus erythematosus","volume":"25","author":"Miceli","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.medj.2026.101187_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medj.2026.101187_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001068","article-title":"Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies","volume":"11","author":"Figueroa-Parra","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.medj.2026.101187_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41584-023-00993-7","article-title":"Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce","volume":"19","author":"Connelly","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.medj.2026.101187_bib6","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/S0140-6736(26)00691-4","article-title":"Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"407","author":"Clowse","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101187_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101187_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101187_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.43350","article-title":"Epidermal Interferon-kappa Drives Cutaneous Lupus-Like Lesions, Photosensitivity, and Systemic Autoimmunity In Vivo","volume":"78","author":"Klein","year":"2026","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medj.2026.101187_bib10","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.immuni.2024.09.004","article-title":"Type I IFN drives unconventional IL-1\u03b2 secretion in lupus monocytes","volume":"57","author":"Caielli","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101187_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(26)00463-0","article-title":"Enpatoran, a Toll-like receptor 7\/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial","volume":"407","author":"Morand","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101187_bib12","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1016\/S2665-9913(25)00337-6","volume":"8","author":"Morand","year":"2026","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.medj.2026.101187_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70059","article-title":"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll-Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study","volume":"7","author":"Hosein","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.medj.2026.101187_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101187_bib15","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2665-9913(24)00246-7","article-title":"Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"7","author":"Askanase","year":"2025","journal-title":"Lancet Rheumatol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663402600190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663402600190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:53:18Z","timestamp":1785898398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663402600190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S266663402600190X"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101187","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic lupus erythematosus: Phase 2 trials to watch in 2026","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101187"}}